Zimmer Biomet Holdings Inc
$ 99.87
0.41%
24 Feb - close price
- Market Cap 19,792,392,000 USD
- Current Price $ 99.87
- High / Low $ 101.06 / 99.39
- Stock P/E 28.13
- Book Value 64.95
- EPS 3.55
- Next Earning Report 2026-05-04
- Dividend Per Share $0.96
- Dividend Yield 0.97 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.06 %
- 52 Week High 113.56
- 52 Week Low 84.59
About
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Analyst Target Price
$102.65
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-30 | 2025-08-07 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-07 | 2024-05-02 | 2024-02-08 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 2.42 | 1.9 | 2.07 | 1.81 | 2.31 | 1.74 | 2.01 | 1.94 | 2.2 | 1.65 | 1.82 | 1.89 |
| Estimated EPS | 2.3978 | 1.88 | 1.98 | 1.77 | 2.29 | 1.74 | 1.99 | 1.87 | 2.15 | 1.6 | 1.81 | 1.64 |
| Surprise | 0.0222 | 0.02 | 0.09 | 0.04 | 0.02 | 0 | 0.02 | 0.07 | 0.05 | 0.05 | 0.01 | 0.25 |
| Surprise Percentage | 0.9258% | 1.0638% | 4.5455% | 2.2599% | 0.8734% | 0% | 1.005% | 3.7433% | 2.3256% | 3.125% | 0.5525% | 15.2439% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-30 | 2026-01-30 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 |
| Amount | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZBH
2026-02-25 12:05:48
Zimmer Biomet will showcase new clinical and operational data and its latest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer, Arnold Schwarzenegger, will be a Presidential Guest Speaker, discussing sustained peak performance, teamwork, and thriving under pressure with Zimmer Biomet CEO Ivan Tornos and AAOS President Ned Amendola. The presentation will feature Zimmer Biomet’s "Magnificent Seven" technologies, including robotics, AI-driven navigation, and smart implants, alongside new data on product safety, efficiency, and patient outcomes.
2026-02-25 12:03:48
Magellan Asset Management Ltd increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.6% in the third quarter, holding 600,125 shares valued at $59.11 million. Several other institutional investors also adjusted their positions in ZBH. The company's stock opened at $99.92 and has a market cap of $19.55 billion, with recent positive quarterly earnings surpassing analyst expectations and a declared quarterly dividend of $0.24.
2026-02-25 11:59:23
Solventum (NYSE:SOLV) is set to report its Q4 earnings tomorrow afternoon, with analysts expecting a 5.5% year-on-year revenue decline, reversing last year's increase. Despite a history of exceeding expectations, the stock is down 5.6% over the last month, compared to a 1.9% average decline for its peers in the surgical equipment & consumables - diversified segment. Investors will be watching closely after the company beat revenue and EPS expectations last quarter.
2026-02-24 15:53:36
Zimmer Biomet (ZBH.SW) experienced a significant volume spike on February 24, 2026, pushing its price up 6.38% to CHF75.00, testing resistance near its 50-day average. While technical indicators suggest a tug-of-war, the stock's fundamentals are mixed with a PE of 24.11 and a strong free cash flow yield of 9.15%. Meyka AI rates ZBH.SW a "BUY" (B+ grade), yet forecasts a short-term downside, advising traders to watch for sustained volume above CHF78.58 for a bullish confirmation.
2026-02-24 15:53:30
Smith+Nephew has signed an exclusive U.S. distribution agreement with RMR Ortho for its A’TOMIC™ Nitinol Fixation System, enhancing Smith+Nephew's Trauma, Foot & Ankle, and Hand & Wrist portfolios. This partnership aims to leverage Smith+Nephew’s commercial reach to expand surgeon access to the dynamic compression nitinol fixation option. The deal is expected to contribute to Smith+Nephew's strategic goal of portfolio expansion and deepen surgeon engagement.
2026-02-24 11:51:55
Orthofix Medical Inc. has released its 2025 10-K report, detailing financial performance, business operations, and strategic initiatives. The report highlights increased net sales and gross profit, improved operating and net losses, and the impact of its merger with SeaSpine. Despite financial improvements and strategic moves like product line discontinuation and capital management, the company faces significant challenges including integration issues, competitive pressures, supply chain disruptions, regulatory hurdles, and cybersecurity threats.
